Lyrica's pediatric exclusivity extended in USA

Pfizer (NYSE: PFE) had to swallow a  damaging defeat in a UK lawsuit last week in relation to Lyrica (pregabalin), but a new development has shown that the US pharma giant’s earning power from the pain-relief drug has not yet diminished.

The US Food and Drug Administration (FDA) has granted pediatric exclusivity for Lyrica, thereby extending the period of market exclusivity for the drug by an additional six months to June 30, 2019.

Lyrica is currently approved in the USA for fibromyalgia, diabetic nerve pain, spinal cord injury nerve pain and pain after shingles in adults. It is also approved as adjunctive therapy for the treatment of partial onset seizures in patients four years of age and older.